Objective To observe the efficacy and safety of galantamine in the treatment of mild cognitive impairment (MCI). Methods Eighty patients with diagnosed MCI were divided into two groups by their number of visiting time: the control group (patients with odd numbers, treated by regular therapy) and the study group (patients with even numbers, treated by galantamine), each with 40 cases. Treatment course is 3 months. The clinical efficacy was evaluated before treatment, as well as 1 month and 3 months after treatment through mini mental status examination (MMSE). Results Three months after treatment, MMSE scores were significantly increased both in the study group and the control group, compared with that before treatment. And the change in the study group is particularly obvious. Conclusion Galantamine can significantly improve the cognitive function in patients with mild cognitive impairment, which is also safe and reliable.%目的 观察加兰他敏治疗轻度认知功能障碍的疗效以及安全性.方法 80例诊断为轻度认知功能障碍(MCI)的患者按就诊时间先后顺序随机分成两组:奇数为常规组,偶数为加兰他敏组,各40例.疗程均为3个月.分别在实验前、实验1个月、实验3个月以简易精神状态量表(MMSE)评定疗效.结果 治疗3个月后,常规组和加兰他敏组治疗后MMSE评分均较治疗前有明显增加,差异均有统计学意义,加兰他敏组治疗效果尤其明显.结论 加兰他敏能显著改善轻度认知功能障碍患者的认知功能,而且安全可靠.
展开▼
